share_log

康华生物(300841.SZ):重组六价诺如病毒疫苗(毕赤酵母)获得临床试验批准通知书

Chengdu Kanghua Biological Products (300841.SZ): The phase III clinical trial approval notice for the six-valent Norovirus vaccine (Pichia pastoris) has been obtained.

Zhitong Finance ·  Dec 17, 2024 11:50

Chengdu Kanghua Biological Products (300841.SZ) announced that recently, the company developed a recombinant hexavalent norovirus vaccine (Pichia pastoris...

According to a report from Zhitong Finance APP, Chengdu Kanghua Biological Products (300841.SZ) announced that recently, the company developed a recombinant hexavalent norovirus vaccine (Pichia pastoris) received the "Clinical Trial Approval Notification" issued by the National Medical Products Administration, agreeing to conduct clinical trials for this product.

Upon review, the recombinant hexavalent norovirus vaccine (Pichia pastoris) accepted on September 25, 2024, meets the relevant requirements for pharmaceutical registration, and clinical trials to prevent acute gastroenteritis caused by genotype infections contained in the vaccine are approved.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment